EP3386518A1 — Methods and compositions for treating a serpinc1-associated disorder
Assigned to Genzyme Corp · Expires 2018-10-17 · 8y expired
What this patent protects
The invention relates to iRNA, e.g., double stranded ribonucleic acid (dsRNA), compositions targeting the Serpincl gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of Serpincl and to treat subjects having a Serpincl -associated disease, e.g., …
USPTO Abstract
The invention relates to iRNA, e.g., double stranded ribonucleic acid (dsRNA), compositions targeting the Serpincl gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of Serpincl and to treat subjects having a Serpincl -associated disease, e.g., a bleeding disorder, such as a hemophilia.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.